UBS has lowered its price target for DocMorris from 27 francs to 25 francs, while maintaining a "Sell" rating on the online pharmacy.
Analyst Sebastian Vogel expressed concerns about the company's growth prospects in the prescription drugs sector in Germany, suggesting a potential slowdown in the near future.
The revised target reflects UBS's assessment based on the latest financial figures released by DocMorris.
The study, published on October 16, 2024, indicates that the company's performance may not meet previous expectations, leading to the adjustment in valuation.